The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Prevalence and Predictors of Risk for Type 2 Diabetes Mellitus and Impaired Glucose Tolerance in Polycystic Ovary Syndrome: A Prospective, Controlled Study in 254 Affected Women
Open accessAbstract
Women with polycystic ovary syndrome (PCOS) are insulin resistant, have insulin secretory defects, and are at high risk for glucose intolerance. We performed this study to determine the prevalence of glucose intolerance and parameters associated with risk for this in PCOS women. Two-hundred and fifty-four PCOS women, aged 14-44 yr, were prospectively evaluated at 2 centers, 1 urban and ethnically diverse (n = 110) and 1 rural and ethnically homogeneous (n = 144). The rural PCOS women were compared to 80 control women of similar weight, ethnicity, and age. A 75-g oral glucose challenge was administered after a 3-day 300-g carbohydrate diet and an overnight fast with 0 and 2 h blood samples for glucose levels. Diabetes was categorized according to WHO criteria. The prevalence of glucose intolerance was 31.1% impaired glucose intolerance (IGT) and 7.5% diabetes. In nonobese PCOS women (body mass index, <27 kg/m2), 10.3% IGT and 1.5% diabetes were found. The prevalence of glucose intolerance was significantly higher in PCOS vs. control women (chi2 = 7.0; P = 0.01; odds ratio = 2.76; 95% confidence interval = 1.23-6.57). Variables most associated with postchallenge glucose levels were fasting glucose levels (P < 0.0001), PCOS status (P = 0.002), waist/hip ratio (P = 0.01), and body mass index (P = 0.021). The American Diabetes Association criteria applied to fasting glucose significantly underdiagnosed diabetes compared to the WHO criteria (3.2% vs. 7.5%; chi2 = 4.7; P = 0.046; odds ratio = 2.48; 95% confidence interval = 1.01-6.69). We conclude that 1) PCOS women are at significantly increased risk for IGT and type 2 diabetes mellitus at all weights and at a young age; 2) these prevalence rates are similar in 2 different populations of PCOS women, suggesting that PCOS may be a more important risk factor than ethnicity or race for glucose intolerance in young women; and 3) the American Diabetes Association diabetes diagnostic criteria failed to detect a significant number of PCOS women with diabetes by postchallenge glucose values.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As such, women with PCOS exhibit increased risk of impaired glucose tolerance and T2DM regardless of weight and age [20].”
From Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis (2019) · cites this paper as [20]
In the citing paper
“Approximately 50–70% of women with PCOS have IR and hyperinsulinaemia [128], whereas many also present evidence of glucose intolerance [20].”
From Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis (2019) · cites this paper as [20]
In the citing paper
“In women with PCOS, dysglycemia typically consists of impaired glucose tolerance [12], its prevalence being of almost 30% in both adult women [13] and affected adolescents [14].”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [12]
In the citing paper
“PCOS patients commonly have metabolic complications, such as type 2 diabetes, insulin resistance (IR), and adipose tissue dysfunction (7–9).”
From Circulating Adipokine Levels in Nonobese Women with Polycystic Ovary Syndrome and in Nonobese Control Women: A Systematic Review and Meta-Analysis (2021) · cites this paper as [7]
In the citing paper
“However, women with PCOS generally have hyperandrogenism and lower SHBG [52] and differences at the end of the intervention are again likely related to baseline differences.”
From Weight management interventions in women with and without PCOS: a systematic review (2017) · cites this paper as [52]
In the citing paper
“However, women with PCOS generally have hyperandrogenism and lower SHBG [52] and differences at the end of the intervention are again likely related to baseline differences.”
From Weight management interventions in women with and without PCOS: a systematic review (2017) · cites this paper as [52]
In the citing paper
“In PCOS, other novel CVD risk factors, premature cardiovascular dysfunction and subclinical CVD 29,30,83 have been noted and are related to IR and obesity. 84-89”
From Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline (2011) · cites this paper as [85]
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Sorted by citations
Items 601–700 of 1,388
Celik, C., Abalı, R., Baştu, E., Taşdemir, N., Tasdemir, U. G., & Gul, A. (2013) · Human Reproduction · doi:10.1093/humrep/det002 · Cited by 46
Acupuncture for infertility: Is it an effective therapy?
Huang, D., Huang, G.-Y., Lu, F., Dieterle, S., Neuer, A., & Robert, G. (2011) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-011-0611-8 · Cited by 45
Bhattacharya, S. M. (2007) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2007.00685.x · Cited by 45
Anagnostis, P. G., Paparodis, R. D., Bosdou, J. Κ., Bothou, C., Μacut, D., Goulis, D. G., & Livadas, S. (2021) · Endocrine · doi:10.1007/s12020-021-02801-2 · Cited by 45
Ezeh, U. I., Chen, I. Y.-D., Chen, Y., & Azziz, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa235 · Cited by 46
Víctor, V. M., Rovira‐Llopis, S., Bañuls, C., Díaz‐Morales, N., Castelló, R., Falcón, R., Gómez, M., Rocha, M., & Hernández‐Mijares, A. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0572 · Cited by 46
PPARγ2Pro12Ala Polymorphism and Human Health
He, W. (2009) · PPAR Research · doi:10.1155/2009/849538 · Cited by 46
Advanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS?
Garg, D., & Merhi, Z. O. (2015) · Nutrients · doi:10.3390/nu7125524 · Cited by 46
Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi, Y., Guo, M., Yan, J., Sun, W. C., Zhang, X., Geng, L., Xu, L., & Chen, Z. (2007) · PubMed · Cited by 44
Thomann, R., Rossinelli, N., Keller, U. B., Tirri, B. F., Geyter, C. D., Ruiz, J. C., Kränzlin, M., & Puder, J. J. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893398 · Cited by 43
Pharmacotherapy of polycystic ovary syndrome – an update
Saha, L., Kaur, S., & Saha, P. K. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00916.x · Cited by 43
The impact of androgen actions in neurons on metabolic health and disease
Morford, J. J., Wu, S., & Mauvais‐Jarvis, F. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.09.001 · Cited by 45
Statins in the Treatment of Polycystic Ovary Syndrome
Kodaman, P. H., & Dulęba, A. J. (2008) · Seminars in Reproductive Medicine · doi:10.1055/s-2007-992933 · Cited by 43
Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome
Lydic, M. L., McNurlan, M. A., Bembo, S. A., Mitchell, L., Komaroff, E., & Gelato, M. C. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.11.069 · Cited by 43
Targets to treat metabolic syndrome in polycystic ovary syndrome
Mahalingaiah, S., & Diamanti‐Kandarakis, E. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1101067 · Cited by 44
Polycystic Ovary Syndrome and Insulin: Our Understanding in the Past, Present and Future
Mayer, S., Evans, W. S., & Nestler, J. E. (2015) · Women s Health · doi:10.2217/whe.14.73 · Cited by 46
Insulin resistance and the long-term consequences of polycystic ovary syndrome
Bhathena, R. K. (2011) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2010.539722 · Cited by 44
Implications of circulating irisin and Fabp4 levels in patients with polycystic ovary syndrome
Abalı, R., Yüksel, İ. T., Yüksel, M. A., Bulut, B., İmamoğlu, M., Emirdar, V., Ünal, F., Güzel, S., & Celik, C. (2016) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2016.1174200 · Cited by 43
Metformin during Pregnancy: Effects on Offspring Development and Metabolic Function
Jorquera, G., Echiburú, B., Crisosto, N., Sotomayor‐Zárate, R., Maliqueo, M. A., & Cruz, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00653 · Cited by 46
Bahçeci, M., Tuzcu, A., Canoruç, N., Tüzün, Y., Kıdır, V., & Aslan, Ç. (2004) · Hormone Research in Paediatrics · doi:10.1159/000081973 · Cited by 43
Lunde, O., & Tanbo, T. G. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701705189 · Cited by 43
Lorenz, L. B., & Wild, R. A. (2007) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31802f5197 · Cited by 43
Bahçeci, M., Tuzcu, A., Bahçeci, S., & Tuzcu, Ş. A. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03347025 · Cited by 43
Alexandraki, K., Protogerou, A. D., Papaioannou, T., Piperi, C., Mastorakos, G. P., Lekakis, J. P., Panidis, D., & Diamanti‐Kandarakis, E. (2006) · HORMONES · doi:10.14310/horm.2002.11176 · Cited by 43
Serum fibroblast growth factor 21 levels in polycystic ovary syndrome
Görar, S., Çulha, C., Üç, Z. A., Dellal, F. D., Serter, R., Aral, S., & Aral, Y. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.487587 · Cited by 43
Should patients with polycystic ovarian syndrome be treated with metformin?
Seli, E. U. (2002) · Human Reproduction · doi:10.1093/humrep/17.9.2230 · Cited by 43
Wang, E. T., Ku, I. A., Shah, S. J., Daviglus, M. L., Schreiner, P. J., Konety, S., Williams, O. D., Siscovick, D. S., & Bibbins-Domingo, K. B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1597 · Cited by 42
Dalamaga, Μ., Papadavid, E., Basios, G., Vaggopoulos, V., Rigopoulos, D., Kassanos, D., & Trakakis, E. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.09.014 · Cited by 42
Lerchbaum, E., Theiler‐Schwetz, V., Giuliani, A., & Obermayer-Pietsch, B. M. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1035 · Cited by 44
Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome?
Legro, R. S. (2004) · Human Reproduction · doi:10.1093/humrep/deh322 · Cited by 43
Self-citationSong, D. K., Lee, H., Oh, J.-Y., Hong, Y. S., & Sung, Y.-A. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.4.302 · Cited by 43
Yuan, J., Li, Z., Yu, Y., Wang, X., & Zhao, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1520695 · Cited by 42
Walch, K., Grimm, C., Zeillinger, R., Huber, J. C., Nagele, F., & Hefler, L. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.01.021 · Cited by 43
Yılmaz, M., Ergün, M. A., Karakoç, A., Yurtçu, E., Çakır, N., & Arslan, M. (2006) · Gynecological Endocrinology · doi:10.1080/09513590600733357 · Cited by 42
The nature of FSH induction by GnRH
Miller, W. L., Shafiee-Kermani, F., Strahl, B. D., & Huang, H.-J. (2002) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(02)00614-8 · Cited by 42
Ryu, K.-J., Kim, M. S., Kim, H. K., Kim, Y. J., Yi, K. W., Shin, J., Hur, J. Y., Kim, T., & Park, H. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.12.018 · Cited by 41
Pontikis, C., Yavropoulou, M. P., Toulis, K. A., Kotsa, K., Kazakos, K., Papazisi, A., Gotzamani-Psarakou, A., & Yovos, J. G. (2011) · Journal of Women s Health · doi:10.1089/jwh.2010.2272 · Cited by 43
Diabetes risk score in the diagnostic categories of polycystic ovary syndrome
Moran, L. J., Strauss, B. J., & Teede, H. J. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.01.133 · Cited by 41
Serrano‐Ríos, M. (2002) · Medicina Clínica · doi:10.1016/s0025-7753(02)73455-6 · Cited by 42
Screening for and Treatment of Polycystic Ovary Syndrome in Teenagers
Salmi, D. J., Zisser, H., & Jovanovic, L. G. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422900504 · Cited by 41
The transcription factor 7-like 2 gene and increased risk of type 2 diabetes: an update
Lyssenko, V. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328304d970 · Cited by 41
Treatment of PCOS with metformin and other insulin-sensitizing agents
Seli, E. U., & Dulęba, A. J. (2004) · Current Diabetes Reports · doi:10.1007/s11892-004-0014-8 · Cited by 41
McCartney, C. R., & Marshall, J. C. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1610000 · Cited by 43
Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study
Ladson, G. M., Dodson, W. C., Sweet, S. D., Archibong, A. E., Kunselman, A. R., Demers, L. M., Williams, N. I., Coney, P., & Legro, R. S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.002 · Cited by 40
Self-citationChang, A. Y., Oshiro, J., Ayers, C. R., & Auchus, R. J. (2015) · Clinical Endocrinology · doi:10.1111/cen.12986 · Cited by 40
Reyes-Muñoz, E., Ortega-González, C., Martínez-Cruz, N., Arce-Sánchez, L., Estrada‐Gutiérrez, G., Morán, C., Sánchez-Serrano, A. P., Higareda-Sánchez, R., & la Jara-Díaz, J. F. D. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012107 · Cited by 41
Physiology and Pathology of the Female Reproductive Axis
Bulun, S. E. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00017-1 · Cited by 40
Factors Contributing to Initial Weight Loss Among Adolescents with Polycystic Ovary Syndrome
Geier, L. M., Bekx, M. T., & Connor, E. L. (2012) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2012.06.008 · Cited by 40
Menstrual Health and the Metabolic Syndrome in Adolescents
Tfayli, H. M., & Arslanian, S. A. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1429.024 · Cited by 40
PCOS in Adolescence and Type 2 Diabetes
Carreau, A.-M., & Baillargeon, J.-P. (2015) · Current Diabetes Reports · doi:10.1007/s11892-014-0564-3 · Cited by 40
Jové, M., Pradas, I., Naudí, A., Rovira‐Llopis, S., Bañuls, C., Rocha, M., Portero‐Otín, M., Hernández‐Mijares, A., Víctor, V. M., & Pamplona, R. (2017) · Oncotarget · doi:10.18632/oncotarget.23393 · Cited by 40
Pradas, I., Rovira‐Llopis, S., Naudí, A., Bañuls, C., Rocha, M., Hernández‐Mijares, A., Pamplona, R., Víctor, V. M., & Jové, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-52263-w · Cited by 41
Polycystic Ovary Syndrome and Psychotic Disorder
Doretto, L., Mari, F. C., & Chaves, A. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00543 · Cited by 41
Type 2 diabetes and polycystic ovary syndrome
Legro, R. S. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.04.010 · Cited by 40
Self-citationCalpain-10 variants and haplotypes are associated with polycystic ovary syndrome in Caucasians
Vollmert, C., Hahn, S., Lamina, C., Huth, C., Kolz, M., Schöpfer-Wendels, A., Mann, K., Bongardt, F., Mueller, J. C., Kronenberg, F., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00584.2005 · Cited by 39
Characterization of polycystic ovary syndrome among Flo app users around the world
Jain, T., Negris, O., Brown, D., Galic, I., Salimgaraev, R., & Zhaunova, L. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00719-y · Cited by 37
Polycystic ovary syndrome in adolescents: is there an epidemic?
Arslanian, S. A., & Witchel, S. F. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200202000-00006 · Cited by 39
When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?
Franks, S. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03934.x · Cited by 39
Kalyan, S., Goshtesabi, A., Sarray, S., Joannou, A., & Almawi, W. Y. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021860 · Cited by 38
Associations between vitamin D levels and polycystic ovary syndrome phenotypes
Davis, E. M., Peck, J. D., Hansen, K. R., Neas, B. R., & Craig, L. B. (2019) · Minerva Endocrinologica · doi:10.23736/s0391-1977.18.02824-9 · Cited by 39
Identifying Children at Risk for Obesity, Type 2 Diabetes, and Cardiovascular Disease
Velasquez‐Mieyer, P., Perez-Faustinelli, S., & Cowan, P. A. (2005) · Diabetes Spectrum · doi:10.2337/diaspect.18.4.213 · Cited by 40
Glucose tolerance abnormalities in Australian women with polycystic ovary syndrome
Dabadghao, P., Roberts, B. J., Wang, J. J., Davies, M. J., & Norman, R. J. (2007) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb01273.x · Cited by 39
Kim, J., Choi, Y. M., Hong, M. A., Chae, S. J., Hwang, K., Yoon, S. H., Ku, S., Suh, C. S., & Kim, S. H. (2017) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-017-0953-z · Cited by 40
Roessler, K. K., Birkebaek, C., Ravn, P., Andersen, M. S., & Glintborg, D. (2013) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.12064 · Cited by 38
Tao, T., Wu, P., Wang, Y., & Liu, W. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0243-5 · Cited by 38
Kim, J., Choi, Y. M., Cho, Y. M., Hong, M. A., Chae, S. J., Hwang, K. R., Hwang, S.-S., Yoon, S. H., & Moon, S. Y. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04389.x · Cited by 38
Khan, K. A., Stas, S. N., & Kurukulasuriya, L. R. (2006) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4564.2006.05675.x · Cited by 40
Polycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies
Jacewicz‐Święcka, M., & Kowalska, I. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3054 · Cited by 39
Racial and ethnic differences in the metabolic response of polycystic ovary syndrome
Ezeh, U. I., Chen, Y.-D. I., & Azziz, R. (2020) · Clinical Endocrinology · doi:10.1111/cen.14193 · Cited by 40
Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome
Soares, G. M., Vieira, C. S., Martins, W. P., dos Reis, R. M., de Sá, M. F. S., & Ferriani, R. A. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01877.x · Cited by 38
Cibula, D., Hill, M., Fanta, M., Šindelka, G., & Zivny, J. (2001) · Human Reproduction · doi:10.1093/humrep/16.5.940 · Cited by 38
Second World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1821 · Cited by 37
Pani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6276187 · Cited by 38
Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome
Cheang, K. I., Huszar, J. M., Best, A. M., Sharma, S. T., Essah, P. A., & Nestler, J. E. (2009) · Diabetes and Vascular Disease Research · doi:10.1177/1479164109336050 · Cited by 38
The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin
Glueck, C. J., Goldenberg, N., Streicher, P., & Wang, P. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.11.1557 · Cited by 38
Genetic Basis of Metabolic Abnormalities in Polycystic Ovary Syndrome
Rold??n, B., n, J. L. S. M., & Escobar-Morreale, H. F. (2004) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200404020-00004 · Cited by 39
Antinozzi, C., Marampon, F., Corinaldesi, C., Vicini, E., Sgrò, P., Vannelli, G. B., Lenzi, A., Crescioli, C., & Luigi, L. D. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0686-y · Cited by 37
Type 2 diabetes mellitus in childhood: obesity and insulin resistance.
Schwartz, M. S., & Chadha, A. (2008) · PubMed · Cited by 36
Common single nucleotide polymorphisms in intron 3 of the calpain-10 gene influence hirsutism
Escobar-Morreale, H. F., Peral, B., Villuendas, G., Calvo, R. M., Sancho, J., & Millán, J. L. S. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)03206-x · Cited by 37
Pharmacologic Approaches to the Prevention of Type 2 Diabetes in High Risk Pediatric Patients
Freemark, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021033 · Cited by 36
Metformin and gestational diabetes
Glueck, C. J., Goldenberg, N., Streicher, P., & Wang, P. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0022-0 · Cited by 38
Marinkovic-Radosevic, J., Cigrovski Berkovic, M., Kruezi, E., Bilic-Curcic, I., & Mrzljak, A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.932 · Cited by 35
Saxena, P., Prakash, A., & Nigam, A. (2011) · Journal of Human Reproductive Sciences · doi:10.4103/0974-1208.82355 · Cited by 35
Juan, C., Chen, K.-H., Wang, P., Hwang, J., & Seow, K. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.03.027 · Cited by 36
Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT?
Andersen, M., & Glintborg, D. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0237 · Cited by 38
Polycystic Ovary Syndrome and Hyperandrogenic States
Chang, R. J., & Dumesic, D. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00021-4 · Cited by 41
Cardio‐metabolic risk factors among young infertile women: a systematic review and meta‐analysis
Mulder, C. L., Lassi, Z. S., Grieger, J. A., Alı̀, A., Jankovic‐Karasoulos, T., Roberts, C. T., & Andraweera, P. H. (2020) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16171 · Cited by 36
Pawelczyk, L. A., Spaczyński, R., Banaszewska, B., & Dulęba, A. J. (2004) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2003.09.031 · Cited by 36
Hiperandrogenismo e pele: síndrome do ovário policístico e resistência periférica à insulina
Yarak, S., Bagatin, E., Hassun, K. M., Parada, M. B., & Talarico, S. (2005) · Anais Brasileiros de Dermatologia · doi:10.1590/s0365-05962005000400011 · Cited by 36
Moini, A., Kanani, M., Kashani, L., Hosseini, R., & Hosseini, L. (2015) · Endocrine · doi:10.1007/s12020-014-0426-4 · Cited by 37
Goodarzi, M. O., Erickson, S. W., Port, S. C., Jennrich, R. I., & Korenman, S. G. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00031-3 · Cited by 36
Polycystic ovary syndrome. Revised diagnostic criteria and long-term health consequences
Kousta, E., Tolis, G., & Franks, S. (2005) · HORMONES · doi:10.14310/horm.2002.11151 · Cited by 35
FTO gene variants are not associated with polycystic ovary syndrome in women from Southern Brazil
Ramos, R. B., & Spritzer, P. M. (2015) · Gene · doi:10.1016/j.gene.2015.01.012 · Cited by 35
Cardiovascular and metabolic risks associated with PCOS
Cobin, R. H. (2013) · Internal and Emergency Medicine · doi:10.1007/s11739-013-0924-z · Cited by 35
Li, Y., Ma, Y., Chen, X., Wang, W., Li, Y., Zhang, Q., & Yang, D. (2012) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-012-9839-2 · Cited by 33
Kim, J. Y., Tfayli, H. M., Michaliszyn, S. F., Lee, S., & Arslanian, S. A. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.02.004 · Cited by 38
5α-reductase activity in women with polycystic ovary syndrome: a systematic review and meta-analysis
Wu, C., Wei, K., & Jiang, Z. (2017) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-017-0242-9 · Cited by 36
Polycystic ovary syndrome and periodontal disease: Underlying links- A review
Tanguturi, S. C., & Nagarakanti, S. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_577_17 · Cited by 37
Vrbíková, J., Dvorakova, K., Grimmichová, T., Hill, M., Stanická, S., Cibula, D., Bendlová, B., Stárka, L., & Vondra, K. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.113 · Cited by 35
Anaforoğlu, İ., Algün, E., İnceçayır, Ö., & Ersoy, K. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.0019 · Cited by 35
Metadata
- Authors
- Legro, R. S.
- Affiliations
- Pennsylvania State University (US)
- ORCID
- Legro, R. S.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-01-01
- Volume
- 84
- Issue
- 1
- Pages
- 165-169
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2096126402
- Cited by
- 1,743
- References
- 0
- Citations by year
- 2026: 16 · 2025: 25 · 2024: 36 · 2023: 24 · 2022: 50 · 2021: 64 · 2020: 54 · 2019: 42 · 2018: 43 · 2017: 66 · 2016: 59 · 2015: 88 · 2014: 81 · 2013: 73 · 2012: 84
- FWCI
- 44.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK040605)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K08 HD-O118, U54HD034449)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Keywords
- polycystic ovary syndrome, type 2 diabetes, impaired glucose tolerance, insulin resistance, insulin secretion, diabetes risk factors, prevalence, fasting blood glucose, waist-to-hip ratio, body mass index, ethnic differences, diagnostic criteria, underdiagnosis, oral glucose tolerance test, young women, obesity
- MeSH terms
- Adolescent, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucose Tolerance Test, Humans, Insulin Resistance, Polycystic Ovary Syndrome, Prospective Studies, Risk, Body Mass Index, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
